Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Dec 07, 2021
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®
Nov 19, 2021
EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering
Nov 16, 2021
EyePoint Pharmaceuticals Announces Pricing of Public Offering
Nov 16, 2021
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 13, 2021
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com

MEDIA RELATIONS CONTACT
Amy Phillips
p. 412.327.9499
e. aphillips@greenroompr.com